BidaskClub cut shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) from a hold rating to a sell rating in a report published on Friday morning.

Several other research analysts also recently issued reports on the stock. Cantor Fitzgerald set a $24.00 price objective on shares of Corbus Pharmaceuticals Holdings and gave the stock a buy rating in a report on Monday, July 17th. Noble Financial restated a buy rating on shares of Corbus Pharmaceuticals Holdings in a report on Friday, June 16th. Finally, JMP Securities restated an outperform rating and set a $27.00 price objective (up previously from $20.00) on shares of Corbus Pharmaceuticals Holdings in a report on Monday, April 3rd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $20.50.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded down 0.84% during trading on Friday, hitting $5.90. 136,366 shares of the stock traded hands. The company’s market cap is $296.29 million. The firm has a 50 day moving average price of $6.26 and a 200-day moving average price of $7.16. Corbus Pharmaceuticals Holdings has a one year low of $2.76 and a one year high of $10.78.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). Corbus Pharmaceuticals Holdings had a negative net margin of 874.41% and a negative return on equity of 117.78%. The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $2.50 million. Analysts anticipate that Corbus Pharmaceuticals Holdings will post ($0.77) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/corbus-pharmaceuticals-holdings-inc-crbp-cut-to-sell-at-bidaskclub/1465928.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning increased its position in Corbus Pharmaceuticals Holdings by 3.9% in the second quarter. Creative Planning now owns 173,475 shares of the biopharmaceutical company’s stock valued at $1,093,000 after buying an additional 6,525 shares during the last quarter. Evanson Asset Management LLC increased its position in Corbus Pharmaceuticals Holdings by 1.5% in the second quarter. Evanson Asset Management LLC now owns 20,660 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 300 shares during the last quarter. Credit Suisse AG bought a new position in Corbus Pharmaceuticals Holdings during the first quarter valued at about $157,000. BlueCrest Capital Management Ltd bought a new position in Corbus Pharmaceuticals Holdings during the first quarter valued at about $246,000. Finally, Highbridge Capital Management LLC increased its position in Corbus Pharmaceuticals Holdings by 38.4% in the first quarter. Highbridge Capital Management LLC now owns 73,696 shares of the biopharmaceutical company’s stock valued at $608,000 after buying an additional 20,437 shares during the last quarter. Institutional investors own 28.12% of the company’s stock.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.